In a screening program for antitumor substances from microbial fermentations, a compound was isolated from the mycelium of an Aspergillus species which proved to be the mycotoxin 5-methoxysterigmatocystin. This and the subsequently isolated sterigmatocystin gave significant inhibition of the transplanted mouse leukemias P-388 and L-1210. Preparation and testing of several derivatives of 5-methoxysterigmatocystin suggest that certain functions in the molecule are essential for tumor inhibition. Although slight antitumor effects have been reported for the chemically related aflatoxins, we believe this is the first report of antitumor activity of sterigmatocystins.
In a screening program for antitumor substances from microbial fermentations, a compound was isolated from the mycelium of an Aspergillus species which proved to be the mycotoxin 5-methoxysterigmatocystin. This and the subsequently isolated sterigmatocystin gave significant inhibition of the transplanted mouse leukemias P-388 and L-1210. Preparation and testing of several derivatives of 5-methoxysterigmatocystin suggest that certain functions in the molecule are essential for tumor inhibition. Although slight antitumor effects have been reported for the chemically related aflatoxins, we believe this is the first report of antitumor activity of sterigmatocystins.
During the course of screening fungal fermentations for antitumor effects, weak inhibition of P-388 lymphatic leukemia was noted with filtrates from an Aspergillus species. The original broth had only slight antimicrobial activity and was without effect at 1:10 dilution on either HeLa or KB cells in tissue culture. Refermentations conducted in an effort to optimize conditions gave highly variable antitumor effects. The reason for this became apparent as a result of a preliminary extraction which indicated virtually all the active principle was in the mycelium. A crudely crystalline solid with significant antitumor activity was recovered in the first such extraction. Subsequent isolation and purification established that the active substance was the well-known mycotoxin 5-methoxysterigmatocystin ( Vegetative culture (4 ml) was transferred to a 500-ml Erlenmeyer flask with 100 ml of production medium consisting of 2% glucose, 3% Staclipse J starch, 2% washed brewers' yeast, and 0.5% CaCO,.
The production culture was incubated at 27 C on a shaking machine rotating at 270 rpm. Samples were taken after 5, 6, and 7 days of incubation, and the mycelium was extracted with acetone. The quantity of 5-MS in the extract was estimated chromatographically using a silica gel thin-layer plate and a solvent system consisting of 1% methanol in toluene. The agent was made visible with ultraviolet light. Tank fermentations were carried out with the same vegetative culture medium and production medium as used in flasks. A seed tank with 6 gallons (ca. 23 liters) of vegetative culture medium was inoculated with 100 ml of spore suspension. The culture was incubated for 48 h at 81 F (27.2 C) with 0.7-ft2/min r flow and 3-lb/in2 back pressure without agitators. The 10-gallon (ca. 38 liters) production broth was inoculated with 0.5 gallons (ca. 1.9 liters) of vegetative culture and incubated at 80 F (26.7 C) with 2.7-ft2/min air flow, 15-lb/in2 back pressure, and 300 rpm agitation. Peak yield was obtained at approximately 140 h.
An 800-gallon (ca. 3,040 liters) fermentation was initiated by inoculating 100 gallons (ca. 380 liters) vegetative medium with 1,500 ml of spore suspension. The vegetative culture was incubated for 48 h at 81 F, the air flow rate was 105 liters/min, the back pressure was 5 lb/in2, and the agitation rate was 155 rpm. Forty gallons (ca. 152 liters) of vegetative culture was transferred to 800 gallons of production culture which was incubated at 80 F with 50-ft3/min air flow, strain was grown in Roux bottles on the same agar medium. Cultures were incubated for at least 5 days at 27 C, and spores were suspended in sterile distilled water. To prepare an inoculum for flask fermentations approximately 1 x 108 spores were added to a 500-ml Erlenmeyer flask containing 100 ml of vegetative medium consisting of 3% glucose, 1% Pharmamedia, 1% soy flour, and 0.3% CaCO,. The vegetative culture was incubated at 27 C for 48 h on a shaking machine rotating at 230 rpm. Vegetative culture (4 ml) was transferred to a 500-ml Erlenmeyer flask with 100 ml of production medium consisting of 2% glucose, 3% Staclipse J starch, 2% washed brewers' yeast, and 0.5% CaCOs. The production culture was incubated at 27 C on a shaking machine rotating at 270 rpm. Peak yield was obtained at approximately 140 h.
Isolation. Both sterigmatocystin and 5-MS were isolated by the same procedure. The fermentation broth was filtered at broth pH, and the mycelium was extracted with acetone. After filtration, the extract was concentrated to an essentially aqueous residue that contained some solid precipitated material. The entire mixture was extracted with methylene chloride at pH 10 to 10.5.
The extract was concentrated, dried over MgSO4, and boiled in methanol until crystallization began. After cooling and standing overnight at -10 C, the products were obtained, either sterigmatocystin as silky off-white needles or 5-MS as yellow needles, depending on the original culture. Physical properties of these compounds were found to be identical to those reported in the literature (4, 11 and 121 C, [aJ12, = 0, was prepared by heating at reflux 5-MS with 15% ethanolic potassium hydroxide (3).
Chromatography. Quantitative chemical analysis of mixtures containing 5-MS and/or sterigmatocystin was achieved by chromatography on Quanta/Gram LQDF 19-channel silica gel plates (20 by 20 cm) using a 99:1 toluene-methanol solvent system. Fermentations were also followed by this assay, with the mycelium from 100-ml samples of whole broth being extracted with acetone. The acetone liquor was concentrated to an aqueous mixture and extracted with chloroform, and the organic phase was evaporated to dryness in a tared vessel to give a crude solid for analysis.
From a solution (10 mg/ml) in methylene chloride or chloroform, 40-mg quantities of crude materials were applied to alternate channels 1 cm from the cellulose-silica gel interface. On the same plates, 10-, 20-, and 40-mg spots of pure reference compounds were similarly applied as standards. Plates were then developed in the above system until the solvent front was 15 cm above the cellulose-silica gel. Under these conditions, sterigmatocystin gave a single zone at R, 0.43, whereas 5-MS gave a single zone at R, 0.34. Although not completely resolved in mixtures, these two zones were sufficiently separated to permit quantitation.
Quantitation of the various mixtures was achieved by scanning on a Schoeffel SD3000 densitometer combined with a Schoeffel SDC computer at 366 nm using the transmission mode, a slit width of 0.2, a beam width of 0.25 mm, and length of 7 mm, with the gain set between 600 and 700. Readings were made using a double-beam arrangement, with the reference beam traveling along the adjacent unspotted channel. Readings were in terms of peak areas as plotted on the same chart as the peaks by the computer.
The relative areas of the standards were plotted to give a curve from which to determine the amounts of the mixtures and crude materials. Sterigmatocystin gives a linear plot on rectangular coordinate paper, whereas 5-MS gives an approximately linear plot on semi-log paper.
In vitro tests. Tests for inhibition of microorganisms and for tissue cell culture cytotoxicity were performed as described in a previous report (1) . For the cytotoxicity test HeLa cells were grown in suspension culture and then harvested and diluted in 20% calf serum medium to approximately 3 x 104 cells per ml. Duplicate roller tubes containing 2 mnl of this cell inoculum incubated overnight were dosed with 0.2 ml of each serial 10-fold dilution of sterigmatocystin products dissolved initially in dimethyl sulfoxide and reincubated at 37.5 C. On day 3 after dosing, tubes were read by microscope examination for cell damage and by macroscopic observation of pH change. A tube was considered positive if more than 50% of the cells were not attached to the glass. The two tubes on either side of the point where 50% inhibition of growth appeared to have occurred were subjected to protein determination. Values were obtained photometrically, and the dose required to cause a 50% decrease in net protein production was determined graphically.
In vivo tests. Tests for inhibition of transplanted tumors in mice were performed using procedures similar to those previously reported; lymphatic leukemia L-1210 (2) and lymphatic leukemia P-388 (8) were employed. With both tumors, animals were implanted intraperitoneally with 106 ascitic cells/ mouse. Animals were then treated once daily for 9 days with suspensions of the test drugs. In each experiment, a group -of animals was injected with saline as a control. Evaluation was on the basis of median survival time (MST) in days. The percentage of increase in life span (ILS) was calculated from the formula: ILS = (MST treated/MST control x 100) -100.
RESULTS
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on October 2, 2017 by guest http://aac.asm.org/ Downloaded from against a variety of gram-positive and gram-negative bacteria, yeasts, and fungi. This finding is consistent with the observations of Lillehoj and Ciegler (13) . Of the six sterigmatocystins that we tested, 5-MS was the most potent cytotoxic agent, giving a HeLa protein mean effective dose of 0.00013 ,g/ml. The mean effective dose of the O-acetyl derivative was 0.0062 ,ug/ml, whereas those of the other materials ranged from 0.24 to 0.68 /g/ml.
In vivo effects. The presumptive structures of sterigmatocystin, 5-MS, and 5-MS derivatives are shown in Fig. 1 , and the antitumor effects of these compounds are summarized in Table 1 . The derivatives were usually tested against both tumor systems. Two exceptions to this, as seen in Table 1 , occurred when insufficient compound was available and the test as performed on the single system seemed definitive. Compounds I and III markedly inhibited both L-1210 and P-388 leukemias with peak ILS being approximately twice that of the control life span. These compounds gave similar dose response patterns but did differ slightly in their potency since III was about one-half as potent and one-half as toxic as I. The activity of the acetyl derivative, II, was comparable to that of I in tests on P-388 leukemia since it significantly prolonged host survival over a fourfold dose range. The toxicity and antileukemic effects were considerably lower for compound IV and were entirely absent in the case of V and VI. DISCUSSION Sterigmatocystin was first described by Hatsuda and Kuyama (10) and its proposed structure was revised by Davies et al. (4) . Holker and Kagal reported the isolation of 5-MS in 1968 (11) . There does not appear to be any information in the literature on the biological properties of 5-MS, but it is reasonable to assume that they are comparable to those of sterigmatocystin. Support for this suggestion is given in the present report, since we found that the relationship between toxicity and antitumor effects was similar for the two compounds. Pharmacologi- Results obtained with a limited number of derivatives of 5-MS indicate that the presence of the 1',2' double bond and the fused furan ring system are essential for both toxic and antitumor effects since the dihydro (V) and iso (VI) derivatives of 5-MS proved to be completely inactive. Substitution of methoxyl for hydroxyl at position C-8 greatly reduced biological effects, whereas acetylation at this position caused little or no change. These findings are consistent with those of Engelbrecht and Altenkirk who compared the effects of sterigmatocystin and aflatoxin analogues on primary cell cultures (7) .
We are continuing to synthesize and test sterigmatocystin analogues to elucidate further structure-activity relationships that will identify the sites critical for antitumor effects. Such information may ultimately permit the preparation of compounds with improved therapeutic potential.
